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Nanoscale chemical speciation of β-amyloid/iron
aggregates using soft X-ray spectromicroscopy†
James Everett, *a,b Jake Brooks, b Joanna F. Collingwood b and
Neil D. Telling a
Iron (Fe) is an essential trace element required for healthy brain function. Yet, disrupted iron neurochem-
istry, and the associated formation of aberrantly aggregated protein lesions has been implicated in the
development of multiple degenerative brain disorders including Alzheimer’s disease (AD). Here, nanoscale
resolution soft X-ray spectromicroscopy is used to examine the interaction of β-amyloid (Aβ), a peptide
fundamentally implicated in the development of Alzheimer’s, and ferric (Fe3+) iron. Crucially, by probing
the carbon K (280–320 eV) and iron L2,3 (700–740 eV) edges, both the organic and inorganic (iron)
sample chemistry was established. The co-aggregation of Aβ and iron is known to influence iron chem-
istry, resulting in the chemical reduction of Fe3+ into reactive and potentially toxic ferrous (Fe2+) and zero-
oxidation (Fe0) states. Here, nanoscale (i.e. sub-micron) variations in both iron oxidation state and the
organic composition of Aβ were observed, replicating in vitro the diverse iron chemistry documented in
amyloid plaques from human brain, with the chemical state of iron linked to the conformation state of Aβ.
Furthermore, aggregates were formed that were morphologically and chemically distinct dependent on
the treatment of Aβ prior to the addition of ferric iron. These findings support the hypothesis that Aβ is
responsible for altering iron neurochemistry, and that this altered chemistry is a factor in neurodegenera-
tive processes documented in AD. The methods applied here, combining nanoscale-resolution imaging
and high chemical sensitivity, enabled discovery of the nanoscale heterogeneity in the iron and carbon
chemistry of in vitro aggregates, and these approaches have scope for wider application in metallomics.
Introduction
The transition metal iron is vital for healthy brain function,
acting as a co-factor in numerous brain processes.1–4 The
maintenance of brain iron homeostasis is fundamental to its
well-being, and multiple complex mechanisms exist to main-
tain this balance.1,4 Although essential, iron can convey neuro-
toxic effects when mishandled in the brain.4–6 Reactive labile
iron can partake in Fenton redox chemistry, producing reactive
oxygen species (ROS) capable of inducing oxidative stress, and
ultimately cell death.5–7 Chemically-reduced, low-oxidation-
state iron (<3+) can catalyse these reactions, driving ROS
production.6
Perturbed iron homeostasis has been observed in numer-
ous degenerative brain disorders including Alzheimer’s
disease (AD),3,8–10 indicating a link between altered brain iron
handling and the onset of neurodegeneration. Disrupted iron
homeostasis has also been implicated in the formation of the
two hallmark protein lesions of AD: neurofibrillary tangles
composed of hyperphosphorylated tau,11–13 and amyloid
plaques composed of the peptide β-amyloid (Aβ).13–15 More
specifically, chemically-reduced, low-oxidation-state iron has
been observed co-localized to amyloid plaques in Alzheimer’s
affected tissues.16–18 Such metal forms are not commonplace
in disease-free brains,18 suggesting their formation to be a
result of Aβ interaction with endogenous brain iron. As
increased oxidative burdens and related oxidative stress are
recognised as key early stage events in the development of
AD,19 the aberrant formation of low-oxidation-state iron may
be fundamental to Alzheimer’s disease pathogenesis.
Moreover, iron has been shown to influence the aggregation
dynamics of Aβ,20–23 potentially enhancing the toxicity of Aβ,
further implicating Aβ/iron interaction in Alzheimer’s disease
aetiology.
Despite these observations, the chemistry of Aβ and iron
interaction is not fully understood, whilst the chemical state
and origin of iron associated with amyloid pathologies in AD
requires further investigation. To date, metal-targeting thera-
pies in AD and other neurodegenerative diseases have been
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limited in their success.24 One reason may be a lack of drug
specificity, resulting in depletion of metal stores required to
sustain neuronal health. Thus it is of paramount importance
to characterise metal phases solely associated with disease
states, and distinguish them from normally metabolized
metals.
Synchrotron-based X-ray techniques offer a unique means
to characterize metal (bio)chemistry in AD to an exceptional
level of chemical and spatial detail.16,17 In our previous publi-
cations we demonstrated Aβ to chemically-reduce ferric (Fe3+)
iron into a ferrous (Fe2+) state in vitro using X-ray absorption
spectroscopy,25,26 providing a potential origin for the low-oxi-
dation-state iron observed in AD tissues in vivo. Using this
approach, we provided an averaged iron oxidation state arising
from Aβ/iron aggregate structures over a spatial scale of ca.
100 µm2.
However, our more recent chemical speciation of amyloid
pathology from AD tissues17 has demonstrated metal and
organic sample chemistry to vary dramatically over small
(<100 nm) spatial scales. Using nanoscale-resolution soft X-ray
spectromicroscopy in the form of scanning transmission X-ray
microscopy (STXM), we demonstrated complex sample hetero-
geneity, resulting in the identification of sub-micron deposits
of zero-oxidation-state iron (Fe0) within these amyloid struc-
tures,17 that would have been otherwise overlooked using
microfocus techniques.
Thus, to adequately understand the chemistry of Aβ/iron
interaction, nanoscale resolution imaging coupled with
precise chemical sensitivity is of vital importance. In this
microscopy study, STXM and transmission electron
microscopy (TEM) was used to examine the nanoscale chemi-
cal speciation of aggregate structures formed through the
interaction of Aβ(1–42) [the full length form of the Aβ peptide]
and iron(III). Carbon K-edge (280–320 eV) and iron L2,3-edge
(700–740 eV) spectroscopic analysis was combined with high
resolution (ca. 20 nm) microscopy, to monitor the organic
composition and iron oxidation state of the Aβ/iron aggregates.
We report dramatic nanoscale variations in both the carbon
(peptide) and iron chemistry of Aβ/iron aggregates, and the
discrimination of individual sub-micron iron deposits.
Experimental
Preparation of samples
Frozen synthetic Aβ(1–42) (Bachem) was thawed and dissolved
in 100 mM NaOH for 30 minutes at room temperature to
create a 1 mg mL−1 (220 µM) Aβ stock solution. NaOH was
used to dissolve any peptide aggregates that may have formed
during peptide storage, ensuring peptide dissolution to a
monomeric state. The Aβ stock was then diluted in a modified,
phosphate free, Krebs-Hensleit buffer (pH 7.4; 100 mM PIPES
(piperazine-N,N′-bis(2-ethanesulfonic acid), 118.5 mM NaCl,
4.8 mM KCl, 1.2 mM MgSO4, 1.4 mM CaCl2, 11 mM glucose;
all Sigma Aldrich) modelled on the cerebrospinal fluid of the
central nervous system,23 and consistently used in our prior
examination of Aβ/metal interactions.25–27 This buffer contains
physiologically relevant concentrations of both calcium and
magnesium, metals that are known to influence the aggrega-
tion dynamics of β-amyloid.28,29 The buffer PIPES was chosen
as it does not strongly interact with metal ions.30
Two Aβ/iron treatments were then prepared:
(i) To establish how iron(III) integrates into pre-formed Aβ
aggregates, Aβ solutions in KH buffer were allowed to incubate
at 37 °C for a minimum of 48 hours before the addition of
iron(III) nitrate (PerkinElmer). The resulting Aβ/iron suspen-
sions were then incubated for a further 30 minutes at 37 °C
before sampling.
(ii) To assess the effect of Aβ and iron(III) co-incubation on a
monomeric Aβ solution, iron(III) nitrate was added to the KH
buffer immediately after Aβ, and the resulting Aβ/iron suspen-
sions were allowed to incubate at 37 °C until the time of
sampling (incubation times are stated in the respective figure
legends).
These two treatment types were designed based on previous
studies where differences in Aβ/iron chemistry were observed
dependent upon the aggregation state of amyloid at the point
of iron loading.22,23
For both treatments, final peptide and iron concentrations
were 35 µM and 370 µM respectively. These concentrations
were chosen to allow efficient detection of Aβ/iron structures
using soft X-ray spectromicroscopy.26 35 µM Aβ solutions were
prepared in KH buffer as an amyloid reference, and 370 µM
iron(III) nitrate suspensions were prepared in KH buffer as an
iron(III) reference. All solutions/suspensions of Aβ/iron were
incubated within sealed microcentrifuge tubes. A flow chart
summarizing the preparation methods used for all sample
types is provided in the ESI (Fig. S1†).
Sampling was performed by depositing 15 µL of Aβ/iron
solutions/suspensions onto silicon oxide membranes (75 nm
window thickness; DuneSciences), and removing excess liquid
using filter paper. Membranes containing Aβ/iron structures
were then mounted onto aluminium plates for soft X-ray
spectromicroscopy (STXM) examination. As STXM experiments
were being performed to assess iron oxidation state following
co-incubation with Aβ, precautions were taken to maintain
anaerobic conditions during sampling and examination of Aβ/
iron material. All sampling was performed in a nitrogen filled
glove bag maintained under a positive pressure with respect to
the ambient conditions. To further prevent changes in iron
oxidation states, membranes containing Aβ/iron structures
were stored within nitrogen filled, O-ring sealed jars. The
mounting of membranes onto STXM plates was performed
within a nitrogen filled glove bag, and anoxic conditions were
maintained during sample transportation to the beamline by
using a nitrogen filled vessel for sample transfer, and purging
of the STXM endstation with nitrogen prior to sample loading.
Scanning transmission X-ray microscopy (STXM)
To assess the nanoscale morphology and chemical compo-
sition of Aβ/iron structures, X-ray spectromicroscopy was per-
formed using STXM.
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STXM experiments were conducted on the Swiss Light
Source (Villigen, Switzerland) PolLux beamline using the
STXM endstation, with a focussed X-ray beam spot size of ca.
20 nm. Energy-specific images of the Aβ/iron structures were
obtained by raster scanning the sample across the focussed
X-ray beam, and recording the intensity of the transmitted
X-rays. To best preserve sample chemistry, scanning (exposure)
times were kept to a minimum (<4 ms per pixel), to minimise
potential photoreduction effects.
To determine the chemical composition of Aβ/iron struc-
tures at a nanoscale spatial resolution, speciation maps were
created by collecting paired images: (i) a “peak” image at the
energy of the feature of interest, and (ii) an “off peak” image a
few eV below this feature. The off peak image was then sub-
tracted from the peak image to create an artefact-free contrast
map (see ESI Fig. S2†), providing the chemical speciation for
the examined sample region. Speciation mapping was per-
formed at the carbon K-edge (288.3 eV) to determine Aβ mor-
phology, and the iron L3-edge (710 eV) to show iron
distribution.
X-ray absorption spectra, providing detailed information
regarding the chemical state of the sample material (e.g. iron
oxidation state) were generated by collecting a series of
images, called a stack, of a given sample area at multiple ener-
gies across a desired energy range (e.g. the iron L2,3-absorption
edge [700–740 eV], or the carbon K-absorption edge [280–320
eV]). For each stack image, transmitted X-ray intensities were
converted to optical density using regions that did not contain
any sample material. This conversion removes any background
absorption features attributable to the beamline. By using this
approach, X-ray absorption spectra can be generated from
every pixel of a stack image. This allows the chemical compo-
sition of highly localized regions (20 nm) of interest to be
determined to an exceptionally high level of detail. To mini-
mize X-ray induced damage to carbon-based structures,
carbon K-edge spectromicroscopy was performed prior to
higher energy iron L2,3-edge spectroscopy.
STXM data processing was performed using the aXis 2000
software package (http://unicorn.mcmaster.ca/aXis2000.html).
X-ray microscopy images were adjusted for brightness and con-
trast using ImageJ software. Grey scale X-ray microscopy
images were converted to false colour and recombined as over-
lays to create coloured composite images.
Analysis of X-ray absorption spectra
To provide a quantitative estimate of the relative proportion of
iron phases contributing to measured iron L2,3-edge X-ray
absorption spectra in these experiments, spectra were fitted to
reference iron X-ray absorption spectra using a non-linear least
squares fitting procedure.
Four reference iron L2,3-edge X-ray absorption spectra
obtained from ferritin, FeCl2, magnetite and an Fe film (see
Fig. S3†) were used to estimate the relative contribution of
Fe3+, Fe2+, Fe3O4 and Fe
0 to the displayed experimental iron
L2,3-edge spectra. The iron L2,3-edge absorption features from
ferritin are consistent with a pure ferric phase and it was there-
fore chosen as a suitable ferric (Fe3+) standard for fitting.
Furthermore, this ferritin spectrum is representative of a bio-
logically-sourced ferric phase. The iron L2,3-edge absorption
features of FeCl2 are consistent with a pure ferrous (Fe
2+)
phase and it was used as a ferrous standard. Magnetite (Fe3O4)
was chosen as this phase has previously been observed in
amyloid structures from Alzheimer’s disease tissue.17,31,32
Inclusion of a magnetite reference spectrum for fitting was
further required as this mixed-valence (Fe2+/3+) phase provides
a unique iron L2,3-edge absorption spectrum, that is not
simply a sum of its principal Fe2+ and Fe3+components. The
Fe0 reference spectrum used for fitting was obtained from Fe0
film standards prepared and measured under vacuum to
prevent oxidation.33 Like magnetite, Fe0 was included in the
fitting process owing to our previous observation of Fe0 nano-
particles in amyloid structures from Alzheimer’s disease
tissue.17
Reference spectra were appropriately scaled by normalizing
the X-ray absorption intensity for each iron phase to the inte-
grated intensity over the iron L2,3 absorption edges, as
described in our previous work (see also Fig. S4†).17 A visual-
isation of the energy ranges used for fitting, and an example
overlay of an experimental spectrum and its corresponding fit
are provided in ESI Fig. S5 and S6† respectively.
A table listing the strength of fit for all displayed experi-
mental iron L2,3-edge absorption spectra is provided in the ESI
(Table S1†). An error value of ±2% for each iron phase is used
in spectral fitting. This error value is due to ambiguity in the
uniqueness of fit owing to noise in the experimental iron L2,3-
edge X-ray absorption spectra.
Transmission electron microscopy
Transmission electron microscopy (TEM) was performed using
a JEOL 1230 microscope operating at 100 kV. No positive or
negative stains were used during TEM microscopy. TEM was
performed last, to avoid any scope for electron beam induced
changes to sample chemistry prior to STXM analysis.
Results & discussion
TEM images and STXM analysis of four Aβ/iron aggregates
formed under the two described incubation conditions are
provided in Fig. 1–4. A further four Aβ/iron aggregates are dis-
played in the ESI Fig. S8–11.† TEM images from Aβ aggregates
formed in the absence of iron are shown in Fig. 5.
Pre-incubated Aβ
As previously described,26,34 TEM examination of Aβ samples
allowed to incubate in KH buffer for a minimum of 48 h prior
to the addition of iron(III) led to the observation of extensive
firbillar aggregates containing electron dense regions (Fig. 1–
and 2, S1†; see also Fig. 3 in ref. 34). STXM speciation
mapping performed at the carbon K-edge to observe peptide
distribution, showed peptide structure to closely resemble the
aggregates observed under TEM (Fig. 1a and 2b), confirming
Inorganic Chemistry Frontiers Research Article


























































































these aggregates to be composed of Aβ. Iron L3-edge speciation
mapping of the aggregates (Fig. 1b and 2c) showed regions of
iron accumulation spanning several microns, with iron distri-
bution resembling the peptide morphology in these regions,
indicating that iron had incorporated into the aggregated Aβ
fibrils. For the aggregate shown in Fig. 1, iron was present as
discrete regions of iron deposition, whereas in Fig. 2 iron was
found to be distributed throughout the entire aggregate struc-
ture. These results demonstrate a heterogeneity in iron loading
between Aβ aggregates formed under the same starting experi-
mental conditions. By comparing the iron L3-edge speciation
maps with the TEM images, it was apparent that the most elec-
tron dense regions in these fibrillar aggregates corresponded
to highest levels of iron loading. In addition, Aβ fibrils associ-
ated with iron were poorly defined compared to regions within
the same aggregate devoid of iron (see also Fig. S12†), and
Aβ-only control aggregates formed without the addition of iron
(III) (Fig. 5).
To probe the organic composition of the Aβ/iron structures
in more detail, X-ray spectromicroscopy was performed over
the entire carbon K-edge (280–320 eV). The resulting X-ray
absorption spectra obtained from the aggregates displayed in
Fig. 1 and 2 are shown in panels 1e and 2e respectively. By
examining these spectra, clear differences can be seen, depen-
dent on the level of iron loading in the aggregate region being
examined.
In Fig. 1, spectrum E1 was collected from an aggregate
region containing no detectable iron. This spectrum was com-
posed of two sharp peak features at ca. 285.2 eV and 288.3 eV,
corresponding to the 1s to π* transitions for peptide aromatic
and amide groups respectively, and closely resembled the Aβ
reference spectrum (Fig. 2e [black trace] and ESI Fig. S7†).
Conversely, spectrum E2 was collected from a region of high
iron loading, and displayed a suppressed aromatic feature at
Fig. 1 STXM speciation maps, TEM image, carbon K-edge X-ray
absorption spectra and iron L2,3-edge X-ray absorption spectra from a
Aβ/iron aggregate, formed following 72 hours of Aβ incubation prior to
the addition of iron(III). (a) Carbon K-edge peptide map. (b) Iron L3-edge
map. (c) Composite image showing peptide (cyan) and iron (red)
content. (d) TEM image of the aggregate region highlighted in (c). A TEM
image of the whole aggregate is also shown in ESI Fig. S2.† (e) Carbon
K-edge X-ray absorption spectra from the aggregate regions highlighted
in panels (a) and (d). (f ) Iron L2,3-edge X-ray absorption spectra
(coloured circles) from the regions highlighted in panel (b). The solid
lines for the spectra correspond to best fit curves created by superposi-
tion of suitably scaled iron reference X-ray absorption spectra (see
Fig. S4† and Everett et al., Nanoscale17).
Fig. 2 TEM image, STXM speciation maps, carbon K-edge and iron L2,3-
edge X-ray absorption spectra from a Aβ/iron aggregate, formed follow-
ing 48 hours of Aβ incubation prior to the addition of iron(III). (a) TEM
image. (b) Carbon K-edge peptide map. (c) Iron L3-edge map. (d)
Composite image showing peptide (cyan) and iron (red) content. (e)
Carbon K-edge X-ray absorption spectra from the regions highlighted in
(b). The Aβ(1–42) reference spectrum displayed in ESI Fig. S7† is also
provided [black trace]. (f ) Iron L2,3-edge X-ray absorption spectra from
the regions highlighted in (c). The solid lines for the spectra correspond
to best fit curves created by superposition of suitably scaled iron refer-
ence X-ray absorption spectra.
Research Article Inorganic Chemistry Frontiers


























































































285.2 eV, and a broadening of the amide feature at 288.3 eV,
when compared to the iron-free aggregate region. These
results suggest alterations in Aβ chemical composition upon
iron loading. Spectrum E3, which was collected from an iron-
free region immediately adjacent to the iron-rich region E2
(see Fig. 1d), was consistent with spectrum E1 and the Aβ refer-
ence, demonstrating variations in Aβ composition to occur
over spatial scales 100s of nm in length.
Consistent with the spectrum from the iron-rich aggregate
region of Fig. 1 (spectrum E2), carbon K-edge spectra from
multiple regions of the aggregate in Fig. 2 (where iron was
spread throughout the entire structure) showed a broadened
amide peak and suppressed aromatic peak compared to the Aβ
standard. This altered Aβ carbon K-edge spectra associated
with iron loading was also observed in the Aβ/aggregate shown
in Fig. 3 of ref. 34, which was formed under identical experi-
mental conditions to the aggregates shown in Fig. 1 and 2
here.
The “building block principle” states that X-ray absorption
spectra acquired from complex structures can be divided into
individual contributions from specific functional groups/
bonds.35 Important caveats to this approach are the effects of
delocalization of electronic charge across functional groups
Fig. 3 TEM image, STXM speciation maps, carbon K-edge and iron L2,3-
edge X-ray absorption spectra from a Aβ/iron aggregate, formed follow-
ing 48 hours of Aβ/iron co-incubation. (a) TEM image. (b) Carbon
K-edge peptide map. (c) Iron L3-edge map. (d) Composite image
showing peptide (cyan) and iron (red) content. (e) Carbon K-edge X-ray
absorption spectrum from the region highlighted in (b). (f ) Iron L2,3-
edge X-ray absorption spectra from the regions highlighted in (c). The
solid lines for the spectra correspond to best fit curves created by super-
position of suitably scaled iron reference X-ray absorption spectra.
Fig. 4 TEM image, STXM speciation maps, carbon K-edge and iron L2,3-
edge X-ray absorption spectra from a further Aβ/iron aggregate formed
following 48 hours of Aβ/iron co-incubation. (a) TEM image. (b) Carbon
K-edge peptide map. (c) Iron L3-edge map. (d) Composite image
showing peptide (cyan) and iron (red) content. (e) Carbon K-edge X-ray
absorption spectrum from the region highlighted in (b). (f ) Iron L2,3-
edge X-ray absorption spectra from the regions highlighted in (c). The
solid lines for the spectra correspond to best fit curves created by super-
position of suitably scaled iron reference X-ray absorption spectra.
Fig. 5 TEM images of Aβ aggregates formed without addition of iron.
Inorganic Chemistry Frontiers Research Article


























































































giving rise to new molecular orbitals,35 the effects of changing
bond length on overlap between orbitals36 and practical
restrictions on available energy resolution. We hypothesise
that observed reproducible broadening of the π* amide peak
in carbon K-edge spectra acquired from iron-rich amyloid
regions may be attributable to the formation of an iron–
amyloid composite within these regions giving rise to new
molecular orbitals.
To establish the oxidation state of iron within the amyloid
aggregates, STXM measurements were performed over the iron
L2,3-edge (700–740 eV). In order to provide an estimate of the
relative proportion of iron phases contributing to the
measured iron L2,3-edge X-ray absorption spectra, spectra were
fitted to suitably scaled reference X-ray absorption spectra
using a non-linear least squares fitting procedure (see ref. 17).
Iron L2,3-edge X-ray absorption spectra from different iron-
rich regions of the Aβ/iron aggregates displayed in Fig. 1 and
2, are shown in panels 1f and 2f respectively. For all of these
regions, iron was found to be in a predominantly ferric (Fe3+)
state, with minor contributions from ferrous (Fe2+) iron. Ferric
materials display a low intensity peak at 708 eV followed by a
dominant high-intensity 709.5 eV peak at the L3-edge, and two
further low intensity L2-absorption edge peaks at 721 and 723
eV (see Fig. S3† for reference iron L2,3-edge X-ray absorption
spectra).37 These findings show that the oxidation state of the
starting iron(III) was predominantly preserved where iron was
added to the pre-formed Aβ aggregates.
Aβ/iron co-incubation
Fig. 3 and 4 show TEM images and STXM data from aggregate
structures formed where Aβ and iron(III) were added simul-
taneously to the KH buffer, and allowed to co-incubate for
48 hours.
TEM imaging (Fig. 3a and 4a) showed these aggregates to
be largely amorphous, displaying no clear fibrillar structure.
This was in stark contrast to the aggregate structures shown in
Fig. 1 and 2, which displayed fibril morphology. Carbon
K-edge speciation mapping (Fig. 3b and 4b) and spectromicro-
scopy showed both aggregates to be carbon-dense, providing
carbon K-edge X-ray absorption spectra (Fig. 3e and 4e) largely
consistent with the Aβ reference, confirming these amorphous
structures to be composed of the peptide.
Iron L3-edge mapping (Fig. 3c and 4c) showed iron distri-
bution in these amorphous aggregates to be confined to dis-
crete sub-micron deposits, 100s of nm in diameter. This was
again in contrast to the aggregates shown in Fig. 1 and 2,
where regions of iron loading spanned several microns, within
which iron distribution mirrored peptide morphology. Iron
L2,3-edge X-ray absorption spectra from the aggregate regions
highlighted in Fig. 3c and 4c, are shown in Fig. 3f and 4f
respectively, and reveal a dramatic variation in iron oxidation
state within the aggregates; with both oxidized and chemically-
reduced phases being present.
For the aggregate shown in Fig. 3, fitting of the iron L2,3-
edge X-ray absorption spectrum F1 showed this region to be
composed of pure ferric iron. Fitting of the spectra from
regions F2 and F4 showed evidence of ferrous and/or zero-oxi-
dation-state iron (Fe0), made apparent by an enhanced inten-
sity of the principal Fe2+/Fe0 absorption feature at 708 eV,37
with respect to the Fe3+ absorption feature at 709.5 eV.
Although Fe2+ and Fe0 share a principal L3 absorption energy
at 708 eV, the two phases are distinguishable by the broader
line-shape for the Fe0 spectrum which lacks the splitting seen
for oxide spectra, and the more prominent L2 peak and post-L2
edge absorption intensity for Fe0 (see ESI Fig. S3†).33,37
Fitting of spectrum F3 showed this region to be primarily
composed of the mixed-valence phase magnetite. The presence
of magnetite was determined by a decreased clarity of separ-
ation between the L3-edge absorption features at 708 eV and
709.5 eV when compared to a ferric standard. In magnetite the
low energy Fe3+ peak feature at 708 eV is not discernible,
instead appearing as a shoulder on the 709.5 eV peak
feature.37
Iron L2,3-edge X-ray absorption spectra from the two stron-
gest absorbing regions of the aggregate shown in Fig. 4 are dis-
played in Fig. 4f. Fitting of spectrum F1 showed this region to
be composed of pure ferric iron, whereas region F2 was com-
posed primarily of Fe0, with a minor contribution from Fe3+.
Interestingly, fibrillar aggregates containing extensive
regions of iron accumulation (similar to those shown in Fig. 1
and 2) were also observed where amyloid and iron(III) were
added simultaneously and allowed to co-incubate in the KH
buffer. These aggregates are shown in ESI Fig. S8–S11,† and
further demonstrate a heterogeneity in Aβ/iron aggregate
structures formed under the same initial incubation con-
ditions. In these fibrillar aggregates, iron was observed to
remain in a predominantly ferric state, suggesting a possible
link between Aβ/iron aggregate morphology and iron oxidation
state (vide infra). Additional higher magnification TEM images
are provided in ESI Fig. S12,† with Aβ/iron aggregates being
categorised according to fibril containing or amorphous
morphology.
Addition of iron(III) nitrate to the KH buffer medium in the
absence of Aβ resulted in the precipitation of an insoluble Fe
(OH)3 species as shown in ESI Fig. S13.† Examination of this
iron across the iron L2,3-edge X-ray absorption edge provided
spectra consistent with ferric iron (ESI Fig. S14†).
The data presented shows the chemical reduction of iron
(III) following co-aggregation with Aβ. A clear heterogeneity in
the morphology and chemistry of Aβ/iron aggregates was
apparent, even where aggregates were formed under the same
initial experimental conditions, with two predominant Aβ/iron
aggregate subtypes being observed:
(i) Fibrillar aggregates containing extensive regions of iron
loading, in which iron distribution closely resembled peptide
morphology, indicating that iron was incorporated into the
aggregating Aβ(1–42). This aggregate type was observed both
where Aβ was incubated prior to the addition of iron(III), and
where Aβ and iron(III) were added simultaneously and allowed
to co-incubate. Within these aggregates, iron loading was
found to be heterogeneous and to affect the organic compo-
sition of Aβ. In aggregate regions free of detectable iron, Aβ
Research Article Inorganic Chemistry Frontiers


























































































provided a carbon K-edge X-ray absorption spectrum consist-
ent with experimental Aβ references. However, in aggregate
regions loaded with iron, the Aβ spectrum was altered, with a
suppression of the aromatic absorption peak, and a broadened
amide peak being recorded.34 This altered Aβ spectrum was
highly localized to regions of iron accumulation, with nano-
scale variations in carbon X-ray absorption spectra being
observed between adjacent iron loaded and iron-free aggregate
regions. Iron L2,3-edge measurements showed iron within
these fibrillar aggregates to remain in a predominantly ferric
state, albeit with a minor ferrous component, which varied
subtly in intensity across the aggregate regions, again demon-
strating a heterogeneity in sample chemistry even within indi-
vidual aggregate structures.
(ii) Amorphous aggregates, containing discrete, sub-micron
deposits of iron. This aggregate type was observed only where
Aβ and iron(III) had been added simultaneously and allowed to
co-incubate. The oxidation state of these iron deposits was
found to vary dramatically, with pure ferric and predominantly
low-oxidation-state (<3+) iron regions being found within the
same aggregate structures. This included the presence of zero-
oxidation-state iron (Fe0), a phase not observed in the fibrillar
aggregate type.
This variation in the organic and inorganic composition of
Aβ/iron structures, evident over spatial scales 100s of nm in
length, highlights the necessity of combined nanoscale resolu-
tion imaging and chemical speciation (as provided by STXM)
to examine the role played by metal/protein interactions in
neurodegenerative disorders. Whilst chemically sensitive,
microfocus X-ray techniques typically applied to characterize
metal chemistry in pathological structures (e.g. ref. 38 and 39)
do not offer nanoscale spatial resolution, resulting in a signal
averaging on the micrometre (µm) scale. The use of such tech-
niques would have precluded the identification of the nano-
scale low-oxidation-state iron deposits, including the Fe0 that
we report here, as the signal from Fe0 would have been domi-
nated by the (more) oxidized signal from the surrounding iron.
The highly localized nature of the Fe0 deposits also offers an
explanation as to why such minor phases were not observed in
our previous examination of equivalent Aβ/iron aggregates
using X-ray absorption spectroscopy,26 where the iron signal
was averaged over ca. 100 µm2.
Comparatively, although spatially sensitive, electron-based
measurements induce a significantly higher degree of beam
damage when compared to STXM,40 preventing the quantifi-
cation of iron oxidation state described here. Thus, the com-
bined chemical sensitivity and nanoscale resolution of STXM
provides a powerful tool to establish new insights into the bio-
chemistry of neurodegeneration, and more broadly the role of
metals in biology. Furthermore, anticipated technical develop-
ments to synchrotron facilities (including the completion of
4th generation synchrotron light sources) promise reduced
measurement times and greater levels of sensitivity, allowing
for high-throughput studies of biological systems with STXM,
and the generation of sufficiently large datasets for robust stat-
istical analysis.
The observation of low-oxidation-state iron phases follow-
ing the co-incubation of Aβ and iron(III) is in keeping with pre-
vious publications from our group,25–27 from others who have
described Aβ-mediated reduction of iron(III) in bulk measure-
ments via spectrophotometry,23,41 and cyclic voltammetry evi-
dence reporting the high reduction potential of Aβ–metal
complexes.42,43 Furthermore, these results provide direct evi-
dence that Aβ/iron interaction may serve as an origin for the
nanoscale, chemically-reduced iron phases observed within
amyloid pathology from human AD tissues including Fe0,
which we recently discovered to exist within amyloid plaque
cores for the first time.17 What remains unclear is whether
iron(III) binding to Aβ was required for the chemical reduction
of iron to occur. Determining Aβ–iron binding was not poss-
ible with STXM, and was therefore beyond the scope of this
study. However numerous other works, including those con-
ducted by our group, have examined Aβ–metal iron binding
using more viable techniques for this purpose (e.g. ref. 34, 44
and 45).
It has been proposed that Aβ–metal interactions occurring
in the AD brain could lead to the localized overproduction of
ROS via Fenton chemistry,5,6 resulting in oxidative stress and
disease progression through neuronal failure, and may there-
fore be relevant to disease pathogenesis. Indeed, previous
in vitro evidence shows the chemical reduction of iron(III) by
Aβ to result in the production ROS,41,46 at sufficiently high
levels as to induce cytotoxic effects.22,47 Interestingly this
reported cytotoxic effect was found to be influenced by the
aggregation state of Aβ at the point of iron loading, with tox-
icity only being observed where iron was present throughout
the aggregation process.22 This is consistent with the results
we present here, where Fe0 was observed only in aggregates
formed through the co-incubation of Aβ and iron(III).
The identification of differing aggregate subtypes depen-
dent upon the aggregation state of Aβ at the point of iron
loading in vitro, is relevant to the amyloid structures observed
in our examination of brain tissues from a transgenic mouse
model of AD.16 In these tissues, large fibrillar amyloid struc-
tures were found to be uniformly loaded with iron, with iron
existing predominantly in a ferric state. These iron loaded
structures also displayed an altered carbon signature com-
pared to the surrounding iron-free neuropil. Conversely, amor-
phous amyloid structures in these tissues contained punctate,
nanoscale iron deposits of varying oxidation state, with ferric,
ferrous and magnetite phases being observed. The results pre-
sented herein, suggest that the differing amyloid plaque types
formed in vivo may reflect the conformational state of amyloid
at the point at which the peptide comes into contact with iron.
Specifically, soluble amyloid fragments interacting with iron
may result in the formation of amorphous amyloid plaques
containing nanoscale chemically-reduced iron deposits,
whereas pre-formed insoluble aggregates may sequester iron
into their fibrillar structure upon encountering the metal.
The observation of differing iron oxidation states, depen-
dent upon the aggregation state of Aβ at the point of iron
loading, also raises a series of important questions regarding
Inorganic Chemistry Frontiers Research Article


























































































our understanding of Aβ/iron interaction in AD tissues. Are
soluble Aβ fragments stronger iron reducing agents than in-
soluble Aβ plaques? By extension, are these reactions occurring
intracellularly, extracellularly or both? Is the secretion of Aβ as
insoluble plaques a protective mechanism,48 preventing the
redox cycling of iron and production of ROS by soluble Aβ
fragments?
Conclusions
In conclusion, the results presented demonstrate the co-incu-
bation of Aβ with iron(III) to result in the formation of aggre-
gate structures displaying a heterogeneity in morphology and
nanoscale chemical composition. The chemical reduction of
iron(III) upon co-aggregation with the Aβ(1–42) fragment was
observed, with the extent of this reduction appearing to be
influenced by the conditions of incubation. These findings
implicate Aβ in the formation of the chemically-reduced iron
phases observed in amyloid pathology from human AD
tissues, and suggest Aβ/iron interactions to be a potential
source of toxicity in AD-affected brains, through the generation
of iron phases capable of ROS production.
Low-oxidation-state iron phases associated with the for-
mation of Aβ aggregates may represent a promising target for
viable therapies intended to combat oxidative stress in AD
tissues, thereby hindering disease progression. This could be
achieved by either preventing the co-aggregation of Aβ and
iron, or by targeting the low-oxidation-sate iron directly (e.g.
through iron chelators). By specifically targeting phases such
as Fe0, which have no known biological function, it may be
possible to lower oxidative burdens in AD tissues, without
negatively impacting upon iron stores required to maintain
healthy brain function. Furthermore, phases such as Fe0 are
strongly magnetic and could act as an endogenous marker for
disease diagnosis and staging using magnetically sensitive
imaging techniques such as MRI. Contrast from amyloid
plaques is observed in high resolution pre-clinical and clinical
MRI, so detailed characterization of iron associated with
amyloid deposits may support progress in developing ioniz-
ing–radiation-free sequences sensitive to amyloid burden via
this endogenous contrast. The X-ray spectromicroscopy meth-
odologies used here also demonstrate the value of combining
both chemical sensitivity and nanoscale spatial resolution
when examining pathological inclusions.
Conflicts of interest
There are no conflicts to declare.
Acknowledgements
This work was supported by the Diamond Light Source, EPSRC
doctoral training grant EP/P503981, and EPSRC project grants
EP/N033191/1 and EP/N033140/1. Measurements were per-
formed on the PolLux beamline at the Swiss Light Source, Paul
Scherrer Institute, Villigen, Switzerland, and we thank Dr Joerg
Raabe and Dr Benjamn Watts for their support. We thank
Karen Walker (Keele University) for TEM support.
Notes and references
1 J. R. Connor, S. L. Menzies, J. R. Burdo and P. J. Boyer, Iron
and iron management proteins in neurobiology, Pediatr.
Neurol., 2001, 25, 118–129.
2 D. J. Piñero and J. R. Connor, Iron in the Brain: An
Important Contributor in Normal and Diseased States,
Neuroscientist, 2000, 6, 435–453.
3 L. Zecca, M. B. H. Youdim, P. Riederer, J. R. Connor and
R. R. Crichton, Iron, brain ageing and neurodegenerative
disorders, Nat. Rev. Neurosci., 2004, 5, 863–873.
4 R. J. Ward, F. A. Zucca, J. H. Duyn, R. R. Crichton and
L. Zecca, The role of iron in brain ageing and neurodegen-
erative disorders, Lancet Neurol., 2014, 13, 1045–
1060.
5 D. B. Kell, Iron behaving badly: inappropriate iron chela-
tion as a major contributor to the aetiology of vascular and
other progressive inflammatory and degenerative diseases,
BMC Med. Genomics, 2009, 2, 2.
6 J. Prousek, Fenton chemistry in biology and medicine, Pure
Appl. Chem., 2007, 79, 2325–2338.
7 A. I. Bush, The metallobiology of Alzheimer’s disease,
Trends Neurosci., 2003, 26, 207–214.
8 H. Kozlowski, M. Luczkowski, M. Remelli and D. Valensin,
Copper, zinc and iron in neurodegenerative diseases
(Alzheimer’s, Parkinson’s and prion diseases), Coord.
Chem. Rev., 2012, 256, 2129–2141.
9 Y. Ke and Z. M. Qian, Iron misregulation in the brain: a
primary cause of neurodegenerative disorders, Lancet
Neurol., 2003, 2, 246–253.
10 R. J. Castellani, P. I. Moreira, G. Liu, J. Dobson, G. Perry,
M. A. Smith and X. Zhu, Iron: The redox-active center of
oxidative stress in Alzheimer disease, Neurochem. Res.,
2007, 32, 1640–1645.
11 R. J. Castellani, R. K. Rolston and M. A. Smith, Alzheimer
Disease, Dis.-Mon., 2010, 56, 484–546.
12 M. Goedert, S. S. Sisodia and D. L. Price, Neurofibrillary
tangles and β-amyloid deposits in Alzheimer’s disease,
Curr. Opin. Neurobiol., 1991, 1, 441–447.
13 C. Ballard, S. Gauthier, A. Corbett, C. Brayne, D. Aarsland
and E. Jones, Alzheimer’s disease, Lancet, 2011, 377, 1019–
1031.
14 J. C. Fiala, Mechanisms of amyloid plaque pathogenesis,
Acta Neuropathol., 2007, 114, 551–571.
15 J. Rogers and J. H. Morrison, Quantitative morphology and
regional and laminar distributions of senile plaques in
Alzheimer’s-disease, J. Neurosci., 1985, 5, 2801–2808.
16 N. D. Telling, J. Everett, J. F. Collingwood, J. Dobson, G. van
der Laan, J. J. Gallagher, J. Wang and A. P. Hitchcock, Iron
Biochemistry is Correlated with Amyloid Plaque
Research Article Inorganic Chemistry Frontiers


























































































Morphology in an Established Mouse Model of Alzheimer’s
Disease, Cell Chem. Biol., 2017, 24, 1205–1215.
17 J. Everett, J. F. Collingwood, V. Tjendana-Tjhin, J. Brooks,
F. Lermyte, G. Plascencia-Villa, I. Hands-Portman,
J. Dobson, G. Perry and N. D. Telling, Nanoscale synchro-
tron X-ray speciation of iron and calcium compounds in
amyloid plaque cores from Alzheimer’s disease subjects,
Nanoscale, 2018, 10, 11782–11796.
18 M. A. Smith, P. L. R. Harris, L. M. Sayre and G. Perry, Iron
accumulation in Alzheimer disease is a source of redox-
generated free radicals, Proc. Natl. Acad. Sci. U. S. A., 1997,
94, 9866–9868.
19 A. Nunomura, G. Perry, G. Aliev, K. Hirai, A. Takeda,
E. K. Balraj, P. K. Jones, H. Ghanbari, T. Wataya,
S. Shimohama, S. Chiba, C. S. Atwood, R. B. Petersen and
M. A. Smith, Oxidative damage is the earliest event in
Alzheimer disease, J. Neuropathol. Exp. Neurol., 2001, 60,
759–767.
20 X. Huang, C. S. Atwood, R. D. Moir, M. A. Hartshorn,
R. E. Tanzi and A. I. Bush, Trace metal contamination
initiates the apparent auto-aggregation, amyloidosis, and
oligomerization of Alzheimer’s Aβ peptides, JBIC, J. Biol.
Inorg. Chem., 2004, 9, 954–960.
21 E. House, J. Collingwood, A. Khan, O. Korchazkina,
G. Berthon and C. Exley, Aluminium, iron, zinc and copper
influence the in vitro formation of amyloid fibrils of Aβ 42
in a manner which may have consequences for metal chela-
tion therapy in Alzheimer’s disease, J. Alzheimer’s Dis.,
2004, 6, 291–301.
22 B. Liu, A. Moloney, S. Meehan, K. Morris, S. E. Thomas,
L. C. Serpell, R. Hider, S. J. Marciniak, D. A. Lomas and
D. C. Crowther, Iron Promotes the Toxicity of Amyloid β
Peptide by Impeding Its Ordered Aggregation, J. Biol.
Chem., 2011, 286, 4248–4256.
23 A. Khan, J. P. Dobson and C. Exley, Redox cycling of iron by
Aβ42, Free Radicals Biol. Med., 2006, 40, 557–569.
24 M. T. Nuñez and P. Chana-Cuevas, New Perspectives in
Iron Chelation Therapy for the Treatment of
Neurodegenerative Diseases, Pharmaceuticals, 2018, 11,
109.
25 J. Everett, E. Cespedes, L. R. Shelford, C. Exley,
J. F. Collingwood, J. Dobson, G. van der Laan,
C. A. Jenkins, E. Arenholz and N. D. Telling, Evidence of
Redox-Active Iron Formation Following Aggregation of
Ferrihydrite and the Alzheimer’s Disease Peptide beta-
Amyloid, Inorg. Chem., 2014, 53, 2803–2809.
26 J. Everett, E. Cespedes, L. R. Shelford, C. Exley,
J. F. Collingwood, J. Dobson, G. van der Laan,
C. A. Jenkins, E. Arenholz and N. D. Telling, Ferrous iron
formation following the co-aggregation of ferric iron and
the Alzheimer’s disease peptide beta-amyloid (1–42), J. R.
Soc., Interface, 2014, 11, 20140165.
27 J. Everett, J. Brooks, F. Lermyte, P. B. O’Connor, P. J. Sadler,
J. Dobson, J. F. Collingwood and N. D. Telling, Iron stored
in ferritin is chemically reduced in the presence of aggre-
gating Aβ(1-42), Sci. Rep., 2020, 10, 10332.
28 A. M. Isaacs, D. B. Senn, M. Yuan, J. P. Shine and
B. A. Yankner, Acceleration of Amyloid β-Peptide
Aggregation by Physiological Concentrations of Calcium,
J. Biol. Chem., 2006, 281, 27916–27923.
29 K. Garai, P. Sengupta, B. Sahoo and S. Maiti, Selective
destabilization of soluble amyloid β oligomers by divalent
metal ions, Biochem. Biophys. Res. Commun., 2006, 345,
210–215.
30 M. H. Benn, A. Rauk and T. W. Swaddle, Measurement of
the interaction of aqueous copper(II) with a model amyloid-
β protein fragment—Interference from buffers,
Can. J. Chem., 2011, 89, 1429–1444.
31 J. F. Collingwood, R. K. K. Chong, T. Kasama, L. Cervera-
Gontard, R. E. Dunin-Borkowski, G. Perry, M. Pósfai,
S. L. Siedlak, E. T. Simpson, M. A. Smith and J. Dobson,
Three-Dimensional Tomographic Imaging and
Characterization of Iron Compounds within Alzheimer’s
Plaque Core Material, J. Alzheimer’s Dis., 2008, 14, 235–
245.
32 G. Plascencia-Villa, A. Ponce, J. F. Collingwood,
M. J. Arellano-Jiménez, X. Zhu, J. T. Rogers, I. Betancourt,
M. José-Yacamán and G. Perry, High-resolution analytical
imaging and electron holography of magnetite particles in
amyloid cores of Alzheimer’s disease, Sci. Rep., 2016, 6,
24873.
33 N. D. Telling, G. v. d. Laan, M. T. Georgieva and
N. R. S. Farley, Facility for combined in situ magnetron
sputtering and soft X-ray magnetic circular dichroism, Rev.
Sci. Instrum., 2006, 77, 073903.
34 F. Lermyte, J. Everett, J. Brooks, F. Bellingeri, K. Billimoria,
P. J. Sadler, P. B. O’Connor, N. D. Telling and
J. F. Collingwood, Emerging Approaches to Investigate the
Influence of Transition Metals in the Proteinopathies,
Cells, 2019, 8, 1231.
35 K. Kaznacheyev, A. Osanna, C. Jacobsen, O. Plashkevych,
O. Vahtras, H. Ågren, V. Carravetta and A. P. Hitchcock,
Innershell Absorption Spectroscopy of Amino Acids,
J. Phys. Chem. A, 2002, 106, 3153–3168.
36 J. Stöhr, F. Sette and A. L. Johnson, Near-Edge X-Ray-
Absorption Fine-Structure Studies of Chemisorbed
Hydrocarbons: Bond Lengths with a Ruler, Phys. Rev. Lett.,
1984, 53, 1684–1687.
37 T. J. Regan, H. Ohldag, C. Stamm, F. Nolting, J. Lüning,
J. Stöhr and R. L. White, Chemical effects at metal/oxide
interfaces studied by X-ray-absorption spectroscopy, Phys.
Rev. B: Condens. Matter Mater. Phys., 2001, 64,
214422.
38 L. M. Miller, Q. Wang, T. P. Telivala, R. J. Smith,
A. Lanzirotti and J. Miklossy, Synchrotron-based infrared
and X-ray imaging shows focalized accumulation of Cu and
Zn co-localized with β-amyloid deposits in Alzheimer’s
disease, J. Struct. Biol., 2006, 155, 30–37.
39 J. F. Collingwood, A. Mikhaylova, M. Davidson, C. Batich,
W. J. Streit, J. Terry and J. Dobson, In situ characterization
and mapping of iron compounds in Alzheimer’s disease
tissue, J. Alzheimers Dis., 2005, 7, 267–272.
Inorganic Chemistry Frontiers Research Article


























































































40 J. F. Collingwood and F. Adams, Chemical imaging analysis
of the brain with X-ray methods, Spectrochim. Acta, Part B,
2017, 130, 101–118.
41 X. Huang, C. S. Atwood, M. A. Hartshorn, G. Multhaup,
L. E. Goldstein, R. C. Scarpa, M. P. Cuajungco, D. N. Gray,
J. Lim, R. D. Moir, R. E. Tanzi and A. I. Bush, The Aβ
Peptide of Alzheimer’s Disease Directly Produces Hydrogen
Peroxide through Metal Ion Reduction, Biochemistry, 1999,
38, 7609–7616.
42 D. Jiang, X. Li, R. Williams, S. Patel, L. Men, Y. Wang and
F. Zhou, Ternary Complexes of Iron, Amyloid-β, and
Nitrilotriacetic Acid: Binding Affinities, Redox Properties,
and Relevance to Iron-Induced Oxidative Stress in
Alzheimer’s Disease, Biochemistry, 2009, 48, 7939–7947.
43 L. Guilloreau, S. Combalbert, A. Sournia-Saquet,
H. Mazarguil and P. Faller, Redox Chemistry of Copper–
Amyloid-β: The Generation of Hydroxyl Radical in the
Presence of Ascorbate is Linked to Redox-Potentials and
Aggregation State, ChemBioChem, 2007, 8, 1317–1325.
44 F. Lermyte, J. Everett, Y. P. Y. Lam, C. A. Wootton, J. Brooks,
M. P. Barrow, N. D. Telling, P. J. Sadler, P. B. O’Connor and
J. F. Collingwood, Metal Ion Binding to the Amyloid β
Monomer Studied by Native Top-Down FTICR Mass
Spectrometry, J. Am. Soc. Mass Spectrom., 2019, 30, 2123–
2134.
45 F. Bousejra-ElGarah, C. Bijani, Y. Coppel, P. Faller and
C. Hureau, Iron(II) Binding to Amyloid-β, the Alzheimer’s
Peptide, Inorg. Chem., 2011, 50, 9024–9030.
46 S. C. Bondy, S. X. Guo-Ross and A. T. Truong, Promotion of
transition metal-induced reactive oxygen species formation
by β-amyloid, Brain Res., 1998, 799, 91–96.
47 D. Schubert and M. Chevion, The Role of Iron in Beta
Amyloid Toxicity, Biochem. Biophys. Res. Commun., 1995,
216, 702–707.
48 P. Carrillo-Mora, R. Luna and L. Colin-Barenque, Amyloid
Beta: Multiple Mechanisms of Toxicity and Only Some
Protective Effects?, Oxid. Med. Cell. Longevity, 2014, 2014,
15.
Research Article Inorganic Chemistry Frontiers
Inorg. Chem. Front. This journal is © the Partner Organisations 2021
O
pe
n 
A
cc
es
s 
A
rt
ic
le
. P
ub
lis
he
d 
on
 1
5 
Ja
nu
ar
y 
20
21
. D
ow
nl
oa
de
d 
on
 1
/1
8/
20
21
 1
0:
55
:0
1 
A
M
. 
 T
hi
s 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
C
om
m
on
s 
A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
L
ic
en
ce
.
View Article Online
